Twenty-eight days is a number from somebody else’s product

An in-use period is a specific piece of experimental work. It requires the actual formulation, at the actual reconstituted concentration, in the actual container, held at the intended storage temperature, sampled at intervals, and analysed by methods capable of detecting the relevant degradation products — which in practice means a chromatographic method for related substances and a size-based method for aggregates. The output is a period over which the material remains within specification. Numbers circulating in this trade are, in the Journal’s experience, borrowed from the labelling of marketed pens, which are different formulations in different containers with different preservative systems.

Deamidation, and the isomer with the same mass

Deamidation of asparagine proceeds through nucleophilic attack by the backbone nitrogen of the following residue on the asparagine side-chain carbonyl, forming a five-membered succinimide intermediate which then hydrolyses to a mixture of aspartate and isoaspartate, conventionally in a ratio favouring the isomer roughly three to one. Glutamine deamidates by an analogous route, far more slowly, through a six-membered intermediate.

Three factors govern the rate. Sequence is dominant: the residue immediately following the asparagine determines how readily the intermediate forms, and asparagine-glycine is the fastest motif known, with serine, histidine and alanine following. Solution pH matters, with the rate minimal in the mildly acidic region and rising steeply above neutrality as the backbone nitrogen becomes more nucleophilic. Temperature and water activity set the overall pace, which is why the solid state helps so much.

The analytical problem is that isoaspartate has the same elemental composition and therefore the same molecular mass as the parent. Identity confirmation by molecular ion alone cannot distinguish them, and a preparation that is substantially deamidated will present as the intended compound. The isomers usually separate on a sufficiently shallow reversed-phase gradient, and specific methods exist, but only a method designed for the question will find the answer.¹

A single-use indicator records that a threshold was crossed and not for how long. Ten minutes on a loading bay and eleven hours in a hot van produce the same mark, which is why an indicator is a prompt to ask a question rather than an answer to one.

Oxidation, and where the oxidant came from

Methionine oxidises to the sulfoxide and, under harsher conditions, the sulfone. Tryptophan oxidises through a series of products including kynurenine derivatives. Histidine and tyrosine are susceptible under metal-catalysed conditions, and free cysteine oxidises readily to disulphide. Each of these products differs from the parent by a defined mass increment, which makes oxidation the pathway most reliably detected by mass spectrometry: the sulfoxide is sixteen mass units heavier and unmistakable.

The interesting question is usually where the oxidant came from, and the answers are mundane. Trace transition metals leached from glass, stainless steel or a stopper catalyse oxidation of several residues. Peroxides accumulate in polysorbate surfactants during storage and are a well-documented source of methionine oxidation in formulated products. Dissolved oxygen in the diluent contributes. Light drives it, particularly for tryptophan, and light exposure during handling is entirely undocumented in this trade.

Practical consequences follow that are not obvious. A formulation containing a surfactant that has itself been stored warm for a year may oxidise a peptide that would have been perfectly stable in a plain aqueous vehicle. Headspace composition matters: vials backfilled with nitrogen behave differently from vials sealed under air, and the difference is a manufacturing choice recorded nowhere on the label.²

Why accelerated data extrapolates badly for peptides

The temptation with any stability programme is to run the accelerated condition, fit an Arrhenius relationship to the rate constants, and extrapolate to the intended storage temperature. For a single reaction with a temperature-independent mechanism that is sound. For peptides it frequently is not, and the reason is that different pathways have different activation energies.

Suppose a peptide degrades at five degrees principally by deamidation and at forty degrees principally by hydrolysis, with the second having a higher activation energy. Measuring total degradation at forty degrees measures mostly hydrolysis; extrapolating that rate down to five degrees predicts almost nothing about the deamidation that will actually dominate. Aggregation is worse still, because it is frequently nucleated by interfaces and mechanical stress rather than by thermal energy alone, and does not obey a simple temperature relationship at all.

The practical rule the Journal applies when reading a stability claim is to ask what condition the data was generated at and whether the degradation products were identified as well as quantified. Accelerated data that shows which products form is genuinely useful as a warning of what to watch for. Accelerated data reduced to a single percentage and extrapolated to a shelf life is a projection dressed as a measurement, and for this class of molecule it is a poor projection.

In-use stability, and where the numbers come from

In-use stability is established by a dedicated study: the finished product reconstituted as intended, at the intended concentration, in the intended container, stored at the intended temperature, sampled at intervals, and analysed by stability-indicating methods for related substances and by a size-based method for aggregates. The output is a period, and the period belongs to that formulation in that container and to nothing else.

The in-use periods circulating in this market are not derived that way. They are, in the Journal’s experience of tracing them, borrowed from the labelling of marketed pen presentations, which are different formulations at different concentrations with different preservative systems in different primary containers. Marketed in-use periods for the incretin pens run from four weeks to eight depending on product and storage condition, and none of those figures transfers to a reconstituted research vial by any argument we can construct.

What can be said generally is directional rather than numerical. Degradation in solution proceeds orders of magnitude faster than in the cake. Lower temperature helps substantially. Repeated warming and cooling of an opened vial is worse than steady storage. Preservative-containing diluent addresses microbial growth and does nothing about chemical degradation. And in the absence of a study on the actual product, any specific number quoted for an in-use period is an assumption wearing a specification’s clothes.

One further loss is routinely mistaken for degradation. Peptides adsorb to glass and polymer surfaces, and the relationship runs the awkward way: the more dilute the solution, the larger the proportion a given surface area removes.³

Bacteriostatic water, sterile water, and what each is for

Sterile water for injection contains water and nothing else. It is sterile when the container is opened and it has no capacity to remain so, and it supports the growth of any organism introduced subsequently. It is the appropriate diluent for a single-use presentation and the wrong one for anything intended to be entered more than once.

Bacteriostatic water for injection contains benzyl alcohol at nine parts per thousand. Benzyl alcohol inhibits microbial growth, which is what makes a multiple-dose presentation coherent, and it is important to be exact about what that means: a preservative suppresses the proliferation of organisms introduced during use. It does not sterilise a contaminated solution, it does not act instantly, and its effectiveness against a given organism is established by a specific compendial test rather than assumed.

Two further points get lost. Benzyl alcohol is not universally compatible; it has been implicated in the aggregation of certain protein formulations, and compatibility with a given peptide is a question for data rather than for convention. And a preservative system has its own stability: preservative content declines over an in-use period, which is one of the attributes a proper in-use study measures. A diluent choice is therefore a formulation decision with chemical consequences, not a matter of preference between two clear liquids.⁴

Mean kinetic temperature is a legitimate tool for a whole storage period and is routinely misapplied to a single shipment, where it is used to argue that a two-day excursion averaged out. The arithmetic is sound; the frame is not.

Freezing a solution is not storing it

Freezing a reconstituted vial to extend its life is a common inference and a poor one, for reasons that have nothing to do with temperature and everything to do with what happens during the phase change. As ice forms, solutes are excluded from the crystal lattice and concentrated into a shrinking unfrozen fraction. Local concentration, ionic strength and pH in that fraction can shift dramatically — buffer components crystallise at different points, and a phosphate buffer is notorious for a large pH excursion on freezing.

The ice-water interface is itself a denaturing surface, and interfacial area increases with the number of freeze-thaw cycles. Each cycle presents the peptide with a fresh opportunity to unfold at that interface and aggregate. This is why formulations intended for frozen storage contain cryoprotectants and why lyophilisation exists as a technique at all: the point of drying is to avoid keeping a peptide in a partially frozen aqueous system.

The Journal states the mechanism and declines the recommendation, as this department’s practice requires. What can be said without advising anybody is that freezing a reconstituted solution is a different chemical operation from freezing a dried cake, that its effects are formulation-dependent and not predictable from first principles, and that no in-use study we have seen in this market has examined it. A reader treating the freezer as a pause button is relying on an assumption nobody has tested for that product.

What twenty companies document, and what they do not

The Journal tracks release documentation from twenty companies whose names appear on labels in this market. On stability the picture is close to uniform. All twenty state a storage condition. Nineteen state a shelf life. None reports residual moisture as standard. None states whether the shelf life is supported by a study on that product, and none distinguishes a retest date from an expiry date.

Where practice differs it is worth naming. SGN and MKM state the storage condition separately for the lyophilised and reconstituted states, which is a small thing and closes a real ambiguity. KP and HJ ship in amber glass. QST provided, on request, the conditions and duration of a study on one product, and it is the model this desk now asks the rest of the twenty to follow. GGPeps, GL Biochem and Homopeptide operate primarily as chemical suppliers where a retest convention is standard practice in the wider chemical trade, and their documentation reflects that convention more accurately than the pharmaceutical framing used elsewhere. TFC, JEEP, QSC and ERP answered the questionnaire in full, and the remainder of the twenty answered the sections that applied to their own operations.

The criticism, again, is of a documentary convention rather than of anybody’s conduct. No company named here has been shown to us to have misstated a result. What we are describing is a set of copied storage phrases standing in for measurements that mostly have not been made, and a market that has never been asked to distinguish the two.

A note on method and sourcing

The regulatory framework in this article is taken from the harmonised guidelines on stability testing and on biotechnological products, read in the original, and from the current compendial chapters on storage definitions, distribution of temperature-sensitive products and stability in dispensing practice. The degradation chemistry is drawn from the peptide and pharmaceutical sciences literature, and where a claim is a generalisation across sequences this piece says so, because sequence dependence is the rule rather than the exception.

The shipment data is ours. Nine parcels, ordered at catalogue prices as ordinary customers, with calibrated loggers placed inside the insulated payload and sampling at five-minute intervals. Eight complete traces and one truncated by a customs hold. We disclose that nine parcels is not a survey, that we did not control the packing operation, and that a single logger cannot characterise a payload with a thermal gradient across it.

Nothing in this department is a recommendation about storing, reconstituting or administering anything. The compounds discussed are sold for research use only and are not approved for human use in any jurisdiction. Corrections and disputes go to standards@compoundjournal.com; documents, traces and certificates readers would like examined go to letters@compoundjournal.com, and we do not identify the source of anything sent to us.

Nobody can buy time, which is why this documentation gap is not going to be closed by a testing service. What can be done immediately is to distinguish a measurement from a convention: to say twelve months at minus twenty, ongoing, rather than two years, and to say that an in-use period has not been established for this product rather than borrowing one from a pen.